| pubmed-article:10807250 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10807250 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:10807250 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:10807250 | lifeskim:mentions | umls-concept:C0017638 | lld:lifeskim |
| pubmed-article:10807250 | lifeskim:mentions | umls-concept:C1533691 | lld:lifeskim |
| pubmed-article:10807250 | lifeskim:mentions | umls-concept:C1512653 | lld:lifeskim |
| pubmed-article:10807250 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:10807250 | pubmed:dateCreated | 2000-7-27 | lld:pubmed |
| pubmed-article:10807250 | pubmed:abstractText | Human gliomas are known to be immunosuppressive. Recent reports have suggested novel strategies to overcome this immunosuppression, including immunogene therapy. We examined expression of 10 immunologically important molecules by human gliomas in vitro, and we discuss the implications for immunogene therapy. | lld:pubmed |
| pubmed-article:10807250 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10807250 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10807250 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10807250 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10807250 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10807250 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10807250 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10807250 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10807250 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10807250 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10807250 | pubmed:month | May | lld:pubmed |
| pubmed-article:10807250 | pubmed:issn | 0148-396X | lld:pubmed |
| pubmed-article:10807250 | pubmed:author | pubmed-author:ChengP JPJ | lld:pubmed |
| pubmed-article:10807250 | pubmed:author | pubmed-author:PetrukK CKC | lld:pubmed |
| pubmed-article:10807250 | pubmed:author | pubmed-author:Farr-JonesM... | lld:pubmed |
| pubmed-article:10807250 | pubmed:author | pubmed-author:ParneyI FIF | lld:pubmed |
| pubmed-article:10807250 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10807250 | pubmed:volume | 46 | lld:pubmed |
| pubmed-article:10807250 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10807250 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10807250 | pubmed:pagination | 1169-77; discussion 1177-8 | lld:pubmed |
| pubmed-article:10807250 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10807250 | pubmed:meshHeading | pubmed-meshheading:10807250... | lld:pubmed |
| pubmed-article:10807250 | pubmed:meshHeading | pubmed-meshheading:10807250... | lld:pubmed |
| pubmed-article:10807250 | pubmed:meshHeading | pubmed-meshheading:10807250... | lld:pubmed |
| pubmed-article:10807250 | pubmed:meshHeading | pubmed-meshheading:10807250... | lld:pubmed |
| pubmed-article:10807250 | pubmed:meshHeading | pubmed-meshheading:10807250... | lld:pubmed |
| pubmed-article:10807250 | pubmed:meshHeading | pubmed-meshheading:10807250... | lld:pubmed |
| pubmed-article:10807250 | pubmed:meshHeading | pubmed-meshheading:10807250... | lld:pubmed |
| pubmed-article:10807250 | pubmed:meshHeading | pubmed-meshheading:10807250... | lld:pubmed |
| pubmed-article:10807250 | pubmed:meshHeading | pubmed-meshheading:10807250... | lld:pubmed |
| pubmed-article:10807250 | pubmed:meshHeading | pubmed-meshheading:10807250... | lld:pubmed |
| pubmed-article:10807250 | pubmed:meshHeading | pubmed-meshheading:10807250... | lld:pubmed |
| pubmed-article:10807250 | pubmed:meshHeading | pubmed-meshheading:10807250... | lld:pubmed |
| pubmed-article:10807250 | pubmed:meshHeading | pubmed-meshheading:10807250... | lld:pubmed |
| pubmed-article:10807250 | pubmed:meshHeading | pubmed-meshheading:10807250... | lld:pubmed |
| pubmed-article:10807250 | pubmed:meshHeading | pubmed-meshheading:10807250... | lld:pubmed |
| pubmed-article:10807250 | pubmed:meshHeading | pubmed-meshheading:10807250... | lld:pubmed |
| pubmed-article:10807250 | pubmed:meshHeading | pubmed-meshheading:10807250... | lld:pubmed |
| pubmed-article:10807250 | pubmed:meshHeading | pubmed-meshheading:10807250... | lld:pubmed |
| pubmed-article:10807250 | pubmed:meshHeading | pubmed-meshheading:10807250... | lld:pubmed |
| pubmed-article:10807250 | pubmed:meshHeading | pubmed-meshheading:10807250... | lld:pubmed |
| pubmed-article:10807250 | pubmed:meshHeading | pubmed-meshheading:10807250... | lld:pubmed |
| pubmed-article:10807250 | pubmed:meshHeading | pubmed-meshheading:10807250... | lld:pubmed |
| pubmed-article:10807250 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10807250 | pubmed:articleTitle | Human glioma immunobiology in vitro: implications for immunogene therapy. | lld:pubmed |
| pubmed-article:10807250 | pubmed:affiliation | Department of Surgery, University of Alberta, Edmonton, Canada. | lld:pubmed |
| pubmed-article:10807250 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10807250 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:10807250 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10807250 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10807250 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10807250 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10807250 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10807250 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10807250 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10807250 | lld:pubmed |
